PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition

Cancer Cell

Volumn 30, Issue 2, 2016, Pages 229-242

  Castel, Pau ^a   Ellis, Haley ^a   Bago, Ruzica ^b   Toska, Eneda ^a   Razavi, Pedram ^a   Carmona, F Javier ^a   Kannan, Srinivasaraghavan ^c   Verma, Chandra S ^c,d,e   Dickler, Maura ^a   Chandarlapaty, Sarat ^a   Brogi, Edi ^a   Alessi, Dario R ^b   Baselga, José ^a   Scaltriti, Maurizio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c BIOINFORMATICS INSTITUTE   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPELISIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TRANSCRIPTION FACTOR FOXO; TUBERIN; UNCLASSIFIED DRUG; IMMEDIATE EARLY PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE; TARGET OF RAPAMYCIN KINASE;

ANIMAL TISSUE; ARTICLE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; KNOCKOUT MOUSE; METABOLISM; NUDE MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, KNOCKOUT; MICE, NUDE; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84989925156     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.06.004     Document Type: Article

References (60)

1. Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., Cohen, P., Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7 (1997), 261–269.
2. Alessi, D.R., Pearce, L.R., Garcia-Martinez, J.M., New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal., 2, 2009, pe27.
3. Arencibia, J.M., Pastor-Flores, D., Bauer, A.F., Schulze, J.O., Biondi, R.M., AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochim. Biophys. Acta 1834 (2013), 1302–1321.
4. Biondi, R.M., Kieloch, A., Currie, R.A., Deak, M., Alessi, D.R., The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 20 (2001), 4380–4390.
5. Brunet, A., Bonni, A., Zigmond, M.J., Lin, M.Z., Juo, P., Hu, L.S., Anderson, M.J., Arden, K.C., Blenis, J., Greenberg, M.E., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999), 857–868.
6. Brunet, A., Park, J., Tran, H., Hu, L.S., Hemmings, B.A., Greenberg, M.E., Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell Biol. 21 (2001), 952–965.
7. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
8. Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163 (2015), 506–519.
9. Collins, B.J., Deak, M., Arthur, J.S., Armit, L.J., Alessi, D.R., In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22 (2003), 4202–4211.
10. Costa, C., Ebi, H., Martini, M., Beausoleil, S.A., Faber, A.C., Jakubik, C.T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. Measurement of PIP3 levels reveals an unexpected role for p110beta in early adaptive responses to p110alpha-specific inhibitors in luminal breast cancer. Cancer Cell 27 (2015), 97–108.
11. Currie, R.A., Walker, K.S., Gray, A., Deak, M., Casamayor, A., Downes, C.P., Cohen, P., Alessi, D.R., Lucocq, J., Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem. J. 337 (1999), 575–583.
12. Cybulski, N., Hall, M.N., TOR complex 2: a signaling pathway of its own. Trends Biochem. Sci. 34 (2009), 620–627.
13. Dibble, C.C., Elis, W., Menon, S., Qin, W., Klekota, J., Asara, J.M., Finan, P.M., Kwiatkowski, D.J., Murphy, L.O., Manning, B.D., TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol. Cell 47 (2012), 535–546.
14. Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A.B., Rodon, J., Ibrahim, Y.H., et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med., 5, 2013, 196ra199.
15. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9 (2009), 550–562.
16. Ericson, K., Gan, C., Cheong, I., Rago, C., Samuels, Y., Velculescu, V.E., Kinzler, K.W., Huso, D.L., Vogelstein, B., Papadopoulos, N., Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc. Natl. Acad. Sci. USA 107 (2010), 2598–2603.
17. Frias, M.A., Thoreen, C.C., Jaffe, J.D., Schroder, W., Sculley, T., Carr, S.A., Sabatini, D.M., mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16 (2006), 1865–1870.
18. Fruman, D.A., Rommel, C., PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13 (2014), 140–156.
19. Gan, X., Wang, J., Su, B., Wu, D., Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 286 (2011), 10998–11002.
20. Garcia-Martinez, J.M., Alessi, D.R., mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416 (2008), 375–385.
21. Gasser, J.A., Inuzuka, H., Lau, A.W., Wei, W., Beroukhim, R., Toker, A., SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol. Cell 56 (2014), 595–607.
22. Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J., Sabatini, D.M., Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006), 859–871.
23. Halland, N., Schmidt, F., Weiss, T., Saas, J., Li, Z., Czech, J., Dreyer, M., Hofmeister, A., Mertsch, K., Dietz, U., et al. Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as highly active and selective SGK1 inhibitors. ACS Med. Chem. Lett. 6 (2015), 73–78.
24. Inoki, K., Li, Y., Zhu, T., Wu, J., Guan, K.L., TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002), 648–657.
25. Inoki, K., Li, Y., Xu, T., Guan, K.L., Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003), 1829–1834.
26. Inoki, K., Zhu, T., Guan, K.L., TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003), 577–590.
27. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126 (2006), 955–968.
28. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., Su, B., SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006), 125–137.
29. Jones, K.T., Greer, E.R., Pearce, D., Ashrafi, K., Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol., 7, 2009, e60.
30. Juric, D., Rodon, J., Gonzalez-Angulo, A.M., Burris, H.A., Bendell, J., Berlin, J.D., Middleton, M.R., Bootle, D., Boehm, M., Schmitt, A., et al. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res., 72, 2012 CT-01.
31. Juric, D., Krop, I., Ramanathan, R.K., Xiao, J., Sanabria, S., Wilson, T.R., Choi, Y., Parmar, H., Hsu, J., Baselga, J., Von Hoff, D.D., GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human phase Ia dose escalation study. Cancer Res., 73, 2013, LB-64.
32. Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H., Ellis, H., Ebbesen, S.H., Ainscough, B.J., Ramu, A., Iyer, G., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518 (2015), 240–244.
33. Kamada, Y., Fujioka, Y., Suzuki, N.N., Inagaki, F., Wullschleger, S., Loewith, R., Hall, M.N., Ohsumi, Y., Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol. Cell. Biol. 25 (2005), 7239–7248.
34. Kobayashi, T., Cohen, P., Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem. J. 339 (1999), 319–328.
35. Kobayashi, T., Deak, M., Morrice, N., Cohen, P., Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem. J. 344 (1999), 189–197.
36. Li, Y., Corradetti, M.N., Inoki, K., Guan, K.L., TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29 (2004), 32–38.
37. Liu, P., Gan, W., Chin, Y.R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L.C., Toker, A., et al. PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 5 (2015), 1194–1209.
38. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., Pandolfi, P.P., Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005), 179–193.
39. Manning, B.D., Cantley, L.C., AKT/PKB signaling: navigating downstream. Cell 129 (2007), 1261–1274.
40. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., Cantley, L.C., Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002), 151–162.
41. Matsuo, T., Kubo, Y., Watanabe, Y., Yamamoto, M., Schizosaccharomyces pombe AGC family kinase Gad8p forms a conserved signaling module with TOR and PDK1-like kinases. EMBO J. 22 (2003), 3073–3083.
42. McManus, E.J., Collins, B.J., Ashby, P.R., Prescott, A.R., Murray-Tait, V., Armit, L.J., Arthur, J.S., Alessi, D.R., The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23 (2004), 2071–2082.
43. Menon, S., Dibble, C.C., Talbott, G., Hoxhaj, G., Valvezan, A.J., Takahashi, H., Cantley, L.C., Manning, B.D., Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156 (2014), 771–785.
44. Murray, J.T., Campbell, D.G., Morrice, N., Auld, G.C., Shpiro, N., Marquez, R., Peggie, M., Bain, J., Bloomberg, G.B., Grahammer, F., et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J. 384 (2004), 477–488.
45. Najafov, A., Sommer, E.M., Axten, J.M., Deyoung, M.P., Alessi, D.R., Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem. J. 433 (2011), 357–369.
46. Najafov, A., Shpiro, N., Alessi, D.R., Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem. J. 448 (2012), 285–295.
47. Pearce, L.R., Komander, D., Alessi, D.R., The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11 (2010), 9–22.
48. Potter, C.J., Pedraza, L.G., Xu, T., Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4 (2002), 658–665.
49. Rodrik-Outmezguine, V.S., Chandarlapaty, S., Pagano, N.C., Poulikakos, P.I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., Rosen, N., mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1 (2011), 248–259.
50. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P., Blenis, J., Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101 (2004), 13489–13494.
51. Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., Spooner, E., Carr, S.A., Sabatini, D.M., PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25 (2007), 903–915.
52. Sarbassov, D.D., Guertin, D.A., Ali, S.M., Sabatini, D.M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005), 1098–1101.
53. Silvera, D., Formenti, S.C., Schneider, R.J., Translational control in cancer. Nat. Rev. Cancer 10 (2010), 254–266.
54. Sommer, E.M., Dry, H., Cross, D., Guichard, S., Davies, B.R., Alessi, D.R., Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem. J. 452 (2013), 499–508.
55. Soukas, A.A., Kane, E.A., Carr, C.E., Melo, J.A., Ruvkun, G., Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev. 23 (2009), 496–511.
56. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000), 205–216.
57. Thorpe, L.M., Yuzugullu, H., Zhao, J.J., PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15 (2015), 7–24.
58. Vasudevan, K.M., Barbie, D.A., Davies, M.A., Rabinovsky, R., McNear, C.J., Kim, J.J., Hennessy, B.T., Tseng, H., Pochanard, P., Kim, S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16 (2009), 21–32.
59. Webb, A.E., Brunet, A., FOXO transcription factors: key regulators of cellular quality control. Trends Biochem. Sci. 39 (2014), 159–169.
60. Zhao, B., Lehr, R., Smallwood, A.M., Ho, T.F., Maley, K., Randall, T., Head, M.S., Koretke, K.K., Schnackenberg, C.G., Crystal structure of the kinase domain of serum and glucocorticoid-regulated kinase 1 in complex with AMP PNP. Protein Sci. 16 (2007), 2761–2769.